RESUMEN
INTRODUCTION: Oxidative stress and inflammation are the basic molecular mechanisms in bilirubin neurotoxicity. We aimed to investigate the relationship between serum bilirubin and an antioxidant, anti-inflammatory and neuroprotective peptid, adrenomedullin (AM) levels. METHODS: The correlation between serum bilirubin and AM levels was investigated in a total of 87 newborns. Newborns were further divided into two groups according to the serum bilirubin levels. Group I (with significant hyperbilirubinemia) and Group II (without significant hyperbilirubinemia) were compared with respect to demographic, anthropometric and biochemical parameters including serum AM levels. RESULTS: In the correlation analysis, a significant positive correlation was detected between serum indirect bilirubin and AM levels in 87 newborns (p < 0.001, r = 0.945). In demographic, anthropometric and biochemical comparison of the two study groups, serum indirect bilirubin levels were 21.53 ± 3.59 and 9.37 ± 4.87 mg/dl in Groups I and II, respectively (p < 0.001), and serum AM levels were 1.45 ± 0.06 and 1.28 ± 0.07 ng/ml in Groups I and II, respectively (p < 0.001) CONCLUSION: AM probably plays a significant role in adverse effects and neuronal injury steps of significant hyperbilirubinemia. In parallel with the results of this study the role, effects and physiopathological basis of AM in neonatal hyperbilirubinemia should be established especially with further animal studies. Results of this study may be used in establishing reference values for AM as there are very limited number of studies in newborns.
Asunto(s)
Adrenomedulina/sangre , Bilirrubina/sangre , Estudios de Casos y Controles , Femenino , Humanos , Hiperbilirrubinemia/sangre , Hiperbilirrubinemia/complicaciones , Recién Nacido , Ictericia Neonatal/etiología , Ictericia Neonatal/terapia , Masculino , FototerapiaRESUMEN
UNLABELLED: Herein we report an asphyctic preterm neonate with respiratory distress and prothrombotic risk factors that responded positively to rtPA treatment following 2 attacks of acute thrombosis. CONFLICT OF INTEREST: None declared.
RESUMEN
OBJECTIVES: To assess the immunogenicity of same needle length of hepatitis B vaccine for infants with different birthweights. Previous studies have focused on obese adolescents and adults that have lower titers of antibody response to hepatitis B vaccine. The aim of this study was to compare antibody titers of macrosomic and other neonates for hepatitis B antibody with the same needle length. METHODS: 96 healthy infants were vaccinated at birth, 1, and 6 months of age with hepatitis B vaccine, with follow-up to 7 months of age. Cord blood and seventh month hepatitis B antibody titer were repeated. Infants were divided into three groups, according to their birthweight, as macrosomic, appropriate for gestational age and small for gestational age. The same needle with 26 G and 16 mm length was used for all infants. RESULTS: Macrosomic infants with a birthweight over 4000 g had lower antibody levels than small and appropriate for gestational age infants. CONCLUSIONS: These data support the hypothesis that birthweight has an effect on response to HBV vaccine. Using the same needle length for immunization of macrosomic infants for hepatitis B reveals significantly reduced antibody titers, this can be related also to possible endogenous factors. Further studies are needed to assess appropriate needle length and effects of other factors on vaccine reactogenicity for macrosomic infants.